Daftar Login

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated

MEREK : mbs303

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated

mbs303mbs303cd3cd20t MBS303MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. The

IDR 10.000
IDR 100.000 Disc -90%
Kuantitas